bimagrumab glp-1 Emerging Role of Myostatin Inhibitors in the Management of Glucagon-Like Peptide-1-Associated Sarcopenia and Metabolic Disorders Beyond GLP-1: the next wave

They are not legal to sell as dietary supplements or for human use outside of regulated research contexts

Future RCTs should adopt the NIHNINDS Common Data Elements for DN, pre-specify subgroup analyses based on glycaemic control and medication use, and employ adaptive or platform designs to achieve adequate power while accounting for heterogeneity

ASA consensus-based guidance on preoperative management of patients on glucagon-like peptide-1 receptor agonists

Martnez-NavarroFJMartnez-MorcilloFJLpez-MuozAPardo-SnchezIMartnez-MenchnTCorbaln-VlezRet al

Diagnosis starts with pattern recognition

Pharmacokinetics, distribution, metabolism, and excretion of BPC-157 in animals